Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver
10.3760/cma.j.cn501113-20250103-00003
- VernacularTitle:累及全身多系统的疾病：代谢相关（非酒精性）脂肪性肝病
- Author:
Eda KAYA
1
;
Yusuf YILMAZ
Author Information
1. Department of Internal Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, Bochum, Germany
- Publication Type:Journal Article
- Keywords:
Fatty liver;
Metabolic diseases;
Liver fibrosis;
Diabetes mellitus, type 2;
Diagnosis;
Treatment;
Cardiometabolic risk factors
- From:
Chinese Journal of Hepatology
2025;33(1):77-87
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, extrahepatic malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology is cardiovascular disorders, followed by extrahepatic malignancies, diabetes mellitus, and liver-related complications. Furthermore, the severity of extrahepatic diseases is parallel to the severity of NAFLD. In clinical practice, aware-ness of the associations of concomitant diseases is of major importance for initiating prompt and timely screening and multidisciplinary management of the disease spectrum. In 2020, a consensus from 22 countries redefined the disease as metabolic (dysfunction)-associated fatty liver disease (MAFLD), which resulted in the redefinition of the corresponding population. Although the patients diagnosed with MAFLD and NAFLD mostly overlap, the MAFLD and NAFLD populations are not identical. In this review, we compared the associations of key extrahepatic diseases between NAFLD and MAFLD.
